Compare DERM & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DERM | BGX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 135.2M |
| IPO Year | 2021 | 2010 |
| Metric | DERM | BGX |
|---|---|---|
| Price | $6.40 | $10.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | ★ 256.8K | 58.7K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $10.38 |
| 52 Week High | $9.56 | $12.65 |
| Indicator | DERM | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 53.24 |
| Support Level | $4.84 | $10.76 |
| Resistance Level | $6.71 | $10.97 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 85.90 | 83.67 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.